🇺🇸 FDA
Patent

US 10363286

Peptide inhibition of CCR3-mediated diseases or conditions

granted A61KA61K38/00A61K38/195

Quick answer

US patent 10363286 (Peptide inhibition of CCR3-mediated diseases or conditions) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61K38/195, A61K47/10, A61K47/6813